Ameriprise Financial Inc. Buys 23,007 Shares of Moderna, Inc. (NASDAQ:MRNA)

Ameriprise Financial Inc. lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 10.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,280 shares of the company’s stock after acquiring an additional 23,007 shares during the quarter. Ameriprise Financial Inc. owned 0.06% of Moderna worth $9,784,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Allworth Financial LP grew its position in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. boosted its stake in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the last quarter. Itau Unibanco Holding S.A. grew its holdings in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after acquiring an additional 343 shares during the period. Commonwealth Equity Services LLC increased its position in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after acquiring an additional 345 shares during the last quarter. Finally, Larson Financial Group LLC lifted its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock valued at $53,000 after acquiring an additional 356 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRNA shares. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Barclays reduced their target price on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. UBS Group reduced their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Finally, Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $53.95.

Moderna Stock Up 6.2%

Moderna stock opened at $26.39 on Tuesday. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47. The firm’s fifty day moving average is $27.70 and its 200 day moving average is $35.11. The company has a market cap of $10.21 billion, a price-to-earnings ratio of -2.84 and a beta of 1.99.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same quarter last year, the firm earned ($3.07) EPS. The firm’s revenue for the quarter was down 35.3% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.